Pfizer (PFE) Competitors

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Is PFE or JNJ a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.1%. Pfizer pays out 122.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years and Johnson & Johnson has raised its dividend for 63 consecutive years.

Does the media favor PFE or JNJ?

In the previous week, Johnson & Johnson had 36 more articles in the media than Pfizer. MarketBeat recorded 140 mentions for Johnson & Johnson and 104 mentions for Pfizer. Pfizer's average media sentiment score of 1.32 beat Johnson & Johnson's score of 1.31 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	80 Very Positive mention(s)	11 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	110 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend PFE or JNJ?

Pfizer presently has a consensus price target of $31.92, suggesting a potential upside of 23.47%. Johnson & Johnson has a consensus price target of $170.67, suggesting a potential upside of 6.92%. Given Pfizer's higher probable upside, equities analysts clearly believe Pfizer is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.50
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.56

Does the MarketBeat Community favor PFE or JNJ?

Pfizer received 386 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.98% of users gave Pfizer an outperform vote while only 65.01% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Pfizer	Outperform Votes 1508 68.98%	Underperform Votes 678 31.02%
Johnson & Johnson	Outperform Votes 1122 65.01%	Underperform Votes 604 34.99%

Do institutionals & insiders believe in PFE or JNJ?

68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has stronger valuation and earnings, PFE or JNJ?

Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.63B	2.30	$8.03B	$1.41	18.34
Johnson & Johnson	$88.82B	4.33	$14.07B	$6.65	24.00

Which has more risk & volatility, PFE or JNJ?

Pfizer has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Is PFE or JNJ more profitable?

Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.24% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	12.62%	19.47%	8.09%
Johnson & Johnson	18.20%	34.24%	13.63%

Summary

Johnson & Johnson beats Pfizer on 15 of the 22 factors compared between the two stocks.